Investigation  ||| S:0 E:14 ||| NN
of  ||| S:14 E:17 ||| IN
nutriactive  ||| S:17 E:29 ||| JJ
phytochemical  ||| S:29 E:43 ||| NN
-  ||| S:43 E:45 ||| :
gamma-oryzanol  ||| S:45 E:60 ||| JJ
in  ||| S:60 E:63 ||| IN
experimental  ||| S:63 E:76 ||| JJ
animal  ||| S:76 E:83 ||| NN
models  ||| S:83 E:90 ||| NNS
Gamma-oryzanol  ||| S:90 E:105 ||| JJ
( ||| S:105 E:106 ||| -LRB-
GO ||| S:106 E:108 ||| NNP
)  ||| S:108 E:110 ||| -RRB-
is  ||| S:110 E:113 ||| VBZ
an  ||| S:113 E:116 ||| DT
abundant  ||| S:116 E:125 ||| JJ
dietary  ||| S:125 E:133 ||| JJ
antioxidant  ||| S:133 E:145 ||| NN
that  ||| S:145 E:150 ||| WDT
is  ||| S:150 E:153 ||| VBZ
considered  ||| S:153 E:164 ||| VBN
to  ||| S:164 E:167 ||| TO
have  ||| S:167 E:172 ||| VB
beneficial  ||| S:172 E:183 ||| JJ
effects  ||| S:183 E:191 ||| NNS
in  ||| S:191 E:194 ||| IN
cardiovascular  ||| S:194 E:209 ||| JJ
disease ||| S:209 E:216 ||| NN
,  ||| S:216 E:218 ||| ,
cancer  ||| S:218 E:225 ||| NN
and  ||| S:225 E:229 ||| CC
diabetes ||| S:229 E:237 ||| NN
.  ||| S:237 E:239 ||| .
Other  ||| S:239 E:245 ||| JJ
potential  ||| S:245 E:255 ||| JJ
properties  ||| S:255 E:266 ||| NNS
of  ||| S:266 E:269 ||| IN
GO  ||| S:269 E:272 ||| NNP
include  ||| S:272 E:280 ||| VBP
inhibition  ||| S:280 E:291 ||| VBN
of  ||| S:291 E:294 ||| IN
gastric  ||| S:294 E:302 ||| JJ
acid  ||| S:302 E:307 ||| NN
secretion  ||| S:307 E:317 ||| NNS
and  ||| S:317 E:321 ||| CC
decreased  ||| S:321 E:331 ||| VBD
post-exercise  ||| S:331 E:345 ||| JJ
muscle  ||| S:345 E:352 ||| NN
fatigue ||| S:352 E:359 ||| NN
.  ||| S:359 E:361 ||| .
GO  ||| S:361 E:364 ||| NNP
is  ||| S:364 E:367 ||| VBZ
a  ||| S:367 E:369 ||| DT
unique  ||| S:369 E:376 ||| JJ
mixture  ||| S:376 E:384 ||| NN
of  ||| S:384 E:387 ||| IN
triterpene  ||| S:387 E:398 ||| JJ
alcohol  ||| S:398 E:406 ||| NN
and  ||| S:406 E:410 ||| CC
sterol  ||| S:410 E:417 ||| JJ
ferulates  ||| S:417 E:427 ||| JJ
present  ||| S:427 E:435 ||| NN
in  ||| S:435 E:438 ||| IN
rice  ||| S:438 E:443 ||| NN
bran  ||| S:443 E:448 ||| NN
oil ||| S:448 E:451 ||| NN
,  ||| S:451 E:453 ||| ,
a  ||| S:453 E:455 ||| DT
byproduct  ||| S:455 E:465 ||| NN
of  ||| S:465 E:468 ||| IN
rice  ||| S:468 E:473 ||| NN
processing ||| S:473 E:483 ||| NN
.  ||| S:483 E:485 ||| .
GO  ||| S:485 E:488 ||| NNP
has  ||| S:488 E:492 ||| VBZ
been  ||| S:492 E:497 ||| VBN
studied  ||| S:497 E:505 ||| VBN
by  ||| S:505 E:508 ||| IN
many  ||| S:508 E:513 ||| JJ
researchers  ||| S:513 E:525 ||| NNS
over  ||| S:525 E:530 ||| IN
the  ||| S:530 E:534 ||| DT
last  ||| S:534 E:539 ||| JJ
three  ||| S:539 E:545 ||| CD
decades ||| S:545 E:552 ||| NNS
.  ||| S:552 E:554 ||| .
In  ||| S:554 E:557 ||| IN
particular ||| S:557 E:567 ||| JJ
,  ||| S:567 E:569 ||| ,
the  ||| S:569 E:573 ||| DT
utility  ||| S:573 E:581 ||| NN
of  ||| S:581 E:584 ||| IN
GO  ||| S:584 E:587 ||| NNP
supplementation  ||| S:587 E:603 ||| NN
has  ||| S:603 E:607 ||| VBZ
been  ||| S:607 E:612 ||| VBN
documented  ||| S:612 E:623 ||| VBN
in  ||| S:623 E:626 ||| IN
numerous  ||| S:626 E:635 ||| JJ
animal  ||| S:635 E:642 ||| NN
models ||| S:642 E:648 ||| NNS
.  ||| S:648 E:650 ||| .
A  ||| S:650 E:652 ||| DT
large  ||| S:652 E:658 ||| JJ
variety  ||| S:658 E:666 ||| NN
of  ||| S:666 E:669 ||| IN
species  ||| S:669 E:677 ||| NNS
was  ||| S:677 E:681 ||| VBD
examined ||| S:681 E:689 ||| VBN
,  ||| S:689 E:691 ||| ,
and  ||| S:691 E:695 ||| CC
various  ||| S:695 E:703 ||| JJ
experimental  ||| S:703 E:716 ||| JJ
methodologies  ||| S:716 E:730 ||| NNS
and  ||| S:730 E:734 ||| CC
targets  ||| S:734 E:742 ||| NNS
were  ||| S:742 E:747 ||| VBD
applied ||| S:747 E:754 ||| VBN
.  ||| S:754 E:756 ||| .
The  ||| S:756 E:760 ||| DT
aim  ||| S:760 E:764 ||| NN
of  ||| S:764 E:767 ||| IN
this  ||| S:767 E:772 ||| DT
study  ||| S:772 E:778 ||| NN
was  ||| S:778 E:782 ||| VBD
to  ||| S:782 E:785 ||| TO
summarize  ||| S:785 E:795 ||| VB
the  ||| S:795 E:799 ||| DT
body  ||| S:799 E:804 ||| NN
of  ||| S:804 E:807 ||| IN
research  ||| S:807 E:816 ||| NN
on  ||| S:816 E:819 ||| IN
GO  ||| S:819 E:822 ||| NNP
supplementation  ||| S:822 E:838 ||| NN
in  ||| S:838 E:841 ||| IN
animals  ||| S:841 E:849 ||| NNS
and  ||| S:849 E:853 ||| CC
to  ||| S:853 E:856 ||| TO
examine  ||| S:856 E:864 ||| VB
possible  ||| S:864 E:873 ||| JJ
mechanisms  ||| S:873 E:884 ||| NNS
of  ||| S:884 E:887 ||| IN
GO  ||| S:887 E:890 ||| NNP
action ||| S:890 E:896 ||| NN
.  ||| S:896 E:898 ||| .
Furthermore ||| S:898 E:909 ||| RB
,  ||| S:909 E:911 ||| ,
while  ||| S:911 E:917 ||| IN
the  ||| S:917 E:921 ||| DT
safety  ||| S:921 E:928 ||| NN
of  ||| S:928 E:931 ||| IN
GO  ||| S:931 E:934 ||| NNP
supplementation  ||| S:934 E:950 ||| NN
in  ||| S:950 E:953 ||| IN
animals  ||| S:953 E:961 ||| NNS
has  ||| S:961 E:965 ||| VBZ
been  ||| S:965 E:970 ||| VBN
well  ||| S:970 E:975 ||| RB
documented ||| S:975 E:985 ||| VBN
,  ||| S:985 E:987 ||| ,
studies  ||| S:987 E:995 ||| NNS
demonstrating  ||| S:995 E:1009 ||| VBG
pharmacokinetics ||| S:1009 E:1025 ||| NN
,  ||| S:1025 E:1027 ||| ,
pharmacodynamics  ||| S:1027 E:1044 ||| NN
and  ||| S:1044 E:1048 ||| CC
efficiency  ||| S:1048 E:1059 ||| NN
are  ||| S:1059 E:1063 ||| VBP
less  ||| S:1063 E:1068 ||| RBR
clear ||| S:1068 E:1073 ||| JJ
.  ||| S:1073 E:1075 ||| .
The  ||| S:1075 E:1079 ||| DT
observed  ||| S:1079 E:1088 ||| JJ
differences  ||| S:1088 E:1100 ||| NNS
in  ||| S:1100 E:1103 ||| IN
these  ||| S:1103 E:1109 ||| DT
findings  ||| S:1109 E:1118 ||| NNS
are  ||| S:1118 E:1122 ||| VBP
also  ||| S:1122 E:1127 ||| RB
discussed ||| S:1127 E:1136 ||| VBN
.  ||| S:1136 E:1138 ||| .
